Clinical Trial

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

CERo Therapeutics reports early safety success and dose escalation in its Phase 1 AML trial for CER-1236, a novel cell therapy for high-risk patients.

Dartmouth Cancer Center gains a top designation for using GammaTile, an innovative implant that delivers immediate radiation during brain tumor surgery.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A familiar quit-smoking app has been rebuilt into a powerful research tool, powering Australia's largest cessation trial and setting a new standard.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.